{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:17Z","timestamp":1792724777773,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11899-012-0124-3","type":"journal-article","created":{"date-parts":[[2012,4,26]],"date-time":"2012-04-26T04:43:39Z","timestamp":1335415419000},"page":"235-240","source":"Crossref","is-referenced-by-count":44,"title":["Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas"],"prefix":"10.1007","volume":"7","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Akinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,27]]},"reference":[{"key":"124_CR1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/A:1008200307625","volume":"8","author":"S Ascani","year":"1997","unstructured":"Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Onco. 1997;8:583\u201392.","journal-title":"Ann Onco"},{"key":"124_CR2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol. 1998;9:717\u201320.","journal-title":"Ann Oncol"},{"key":"124_CR3","first-page":"396","volume":"43","author":"S Nakamura","year":"1993","unstructured":"Nakamura S, Koshikawa T, Koike K, et al. Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Acta Pathol Jpn. 1993;43:396\u2013412.","journal-title":"Acta Pathol Jpn"},{"key":"124_CR4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1440-1827.2007.02207.x","volume":"58","author":"R Aoki","year":"2008","unstructured":"Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001\u20132006. Pathol Int. 2008;58:174\u201382.","journal-title":"Pathol Int"},{"key":"124_CR5","volume-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008."},{"key":"124_CR6","volume-title":"Non-Hodgkin\u2019s lymphomas. NCCN clinical practice guidelines in oncology. v.1.2010","author":"National Comprehensive Cancer Network (NCCN)","year":"2010","unstructured":"National Comprehensive Cancer Network (NCCN). Non-Hodgkin\u2019s lymphomas. NCCN clinical practice guidelines in oncology. v.1.2010. Fort Washington, PA: NCCN; 2010."},{"key":"124_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"124_CR8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204\u201310.","journal-title":"J Clin Oncol"},{"key":"124_CR9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.1994.12.5.895","volume":"12","author":"JT Sandlund","year":"1994","unstructured":"Sandlund JT, Pui CH, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1994;12:895\u20138.","journal-title":"J Clin Oncol"},{"key":"124_CR10","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"124_CR11","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117:6756\u201367.","journal-title":"Blood"},{"key":"124_CR12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1349-7006.2010.01820.x","volume":"102","author":"S Sonoda","year":"2011","unstructured":"Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci. 2011;102:295\u2013301.","journal-title":"Cancer Sci"},{"key":"124_CR13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","volume":"116","author":"M Iwanaga","year":"2010","unstructured":"Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211\u20139.","journal-title":"Blood"},{"issue":"Suppl 2","key":"124_CR14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF03165123","volume":"76","author":"K Yamaguchi","year":"2002","unstructured":"Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol. 2002;76 Suppl 2:240\u20135.","journal-title":"Int J Hematol"},{"key":"124_CR15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: A report from the Lymphoma Study Group (1984\u201387). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"124_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"124_CR17","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.seminhematol.2010.01.015","volume":"47","author":"K Tobinai","year":"2010","unstructured":"Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin Hematol. 2010;47 Suppl 1:S5\u20137.","journal-title":"Semin Hematol"},{"key":"124_CR18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375\u201382.","journal-title":"Br J Haematol"},{"key":"124_CR19","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458\u201364.","journal-title":"J Clin Oncol"},{"key":"124_CR20","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177\u201383.","journal-title":"J Clin Oncol"},{"key":"124_CR21","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/sj.onc.1210368","volume":"26","author":"TA Waldmann","year":"2007","unstructured":"Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia\/lymphoma. Oncogene. 2007;26:3699\u2013703.","journal-title":"Oncogene"},{"key":"124_CR22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood-2002-11-3601","volume":"102","author":"Z Zhang","year":"2003","unstructured":"Zhang Z, Zhang M, Ravetch JV, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003;102:284\u20138.","journal-title":"Blood"},{"key":"124_CR23","first-page":"6453","volume":"63","author":"Z Zhang","year":"2003","unstructured":"Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63:6453\u20137.","journal-title":"Cancer Res"},{"key":"124_CR24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.leukres.2005.05.008","volume":"30","author":"F Ravandi","year":"2006","unstructured":"Ravandi F, Faderl S. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res. 2006;30:103\u20135.","journal-title":"Leuk Res"},{"key":"124_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.leu.2404958","volume":"22","author":"C Callens","year":"2008","unstructured":"Callens C, Moura IC, Lepelletier Y, et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia. 2008;22:42\u20138.","journal-title":"Leukemia"},{"key":"124_CR26","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminhematol.2005.12.008","volume":"43","author":"CE Dearden","year":"2006","unstructured":"Dearden CE. Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas. Semin Hematol. 2006;43:S22\u20136.","journal-title":"Semin Hematol"},{"key":"124_CR27","first-page":"1250","volume":"23","author":"K Tobinai","year":"2009","unstructured":"Tobinai K. Current management of adult T-cell leukemia\/lymphoma. Oncology (Williston Park). 2009;23:1250\u20136.","journal-title":"Oncology (Williston Park)"},{"key":"124_CR28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182\u20139.","journal-title":"J Clin Oncol"},{"key":"124_CR29","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.4049\/jimmunol.161.10.5111","volume":"161","author":"D D'Ambrosio","year":"1998","unstructured":"D'Ambrosio D, Iellem A, Bonecchi R, et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998;161:5111\u20135.","journal-title":"J Immunol"},{"key":"124_CR30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1084\/jem.194.6.847","volume":"194","author":"A Iellem","year":"2001","unstructured":"Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194:847\u201353.","journal-title":"J Exp Med"},{"key":"124_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/eji.200324429","volume":"34","author":"M Mariani","year":"2004","unstructured":"Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol. 2004;34:231\u201340.","journal-title":"Eur J Immunol"},{"key":"124_CR32","first-page":"3625","volume":"9","author":"T Ishida","year":"2003","unstructured":"Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625\u201334.","journal-title":"Clin Cancer Res"},{"key":"124_CR33","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1038\/sj.onc.1210984","volume":"27","author":"T Nakayama","year":"2008","unstructured":"Nakayama T, Hieshima K, Arao T, et al. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene. 2008;27:3221\u201332.","journal-title":"Oncogene"},{"key":"124_CR34","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","volume":"10","author":"T Ishida","year":"2004","unstructured":"Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494\u2013500.","journal-title":"Clin Cancer Res"},{"key":"124_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685","volume":"96","author":"D Jones","year":"2000","unstructured":"Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96:685\u201390.","journal-title":"Blood"},{"key":"124_CR36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-08-1808","volume":"15","author":"M Nakagawa","year":"2009","unstructured":"Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2009;15:30\u20138.","journal-title":"Clin Cancer Res"},{"key":"124_CR37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/intimm\/11.1.81","volume":"11","author":"T Imai","year":"1999","unstructured":"Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999;11:81\u20138.","journal-title":"Int Immunol"},{"key":"124_CR38","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-03-2068","volume":"64","author":"R Niwa","year":"2004","unstructured":"Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64:2127\u201333.","journal-title":"Cancer Res"},{"key":"124_CR39","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","volume":"16","author":"T Ishii","year":"2010","unstructured":"Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2010;16:1520\u201331.","journal-title":"Clin Cancer Res"},{"key":"124_CR40","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","volume":"278","author":"T Shinkawa","year":"2003","unstructured":"Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466\u201373.","journal-title":"J Biol Chem"},{"key":"124_CR41","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2141.2007.06947.x","volume":"140","author":"H Yano","year":"2008","unstructured":"Yano H, Ishida T, Imada K, et al. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia\/lymphoma using G-CSF. Br J Haematol. 2008;140:586\u20139.","journal-title":"Br J Haematol"},{"key":"124_CR42","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.4049\/jimmunol.0900699","volume":"183","author":"A Ito","year":"2009","unstructured":"Ito A, Ishida T, Utsunomiya A, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD\/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol. 2009;183:4782\u201391.","journal-title":"J Immunol"},{"key":"124_CR43","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"\u2022 Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591\u20138. This manuscript describes the results of a phase I study of mogamulizumab (KW-0761) in ATL and PTCL, showing encouraging therapeutic efficacy with acceptable toxicity profiles.","journal-title":"J Clin Oncol"},{"key":"124_CR44","first-page":"8356","volume":"29","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Tobinai K, Akinaga S, et al. Reply to R. Suzuki. J Clin Oncol. 2010;29:8356.","journal-title":"J Clin Oncol"},{"key":"124_CR45","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"\u2022 Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837\u201342. This manuscript describes the results of a phase II study of mogamulizumab\/KW-0761 in relapsed patients with ATL, yielding a best overall response rate of 50\u00a0% and median progression-free survival of 5.2\u00a0months.","journal-title":"J Clin Oncol"},{"key":"124_CR46","doi-asserted-by":"crossref","unstructured":"Duvic M, Pinter-Brown L, Foss FM, et al.: Results of a phase 1\/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. [abstract 962]. Presented at the 52nd Annual Meeting of the American Society of Hematology. Orlando, USA; December 4\u20137, 2010.","DOI":"10.1182\/blood.V116.21.962.962"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11899-012-0124-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T08:54:35Z","timestamp":1687424075000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-012-0124-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,27]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1007\/s11899-012-0124-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,27]]}}}